Hyloris Pharmaceuticals SA (0AB6) Share Forecast & Price Target
0AB6 Analyst Ratings
There are no analyst ratings in the last 3 months.
0AB6 Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Christophe dombu | Kepler Capital | EUR 14.30 | buy | 273.37%Upside | Reiterated | 03/26/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Christophe dombu | 03/26/26 | EUR 14.30 | buy | 273.37%Upside | Reiterated | Kepler Capital |
Best Analysts Covering Hyloris Pharmaceuticals SA
Copying Christophe dombu's trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of -0.61% per trade.
Copying Christophe dombu's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -16.81% per trade.
Copying Christophe dombu's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -37.06% per trade.
0AB6 Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 0 | 0 | 0 |
In the current month, 0AB6 has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0AB6 average Analyst price target in the past 3 months is ―.
0AB6 Financial Forecast
0AB6 Earnings Forecast
Next quarter’s earnings estimate for 0AB6 is -EUR 0.07 with a range of ― to ―. The previous quarter’s EPS was -EUR 0.07. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
0AB6 Sales Forecast
Next quarter’s sales forecast for 0AB6 is EUR 4.70M with a range of ― to ―. The previous quarter’s sales results were EUR 4.70M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
